Dıagnostıc Value of IMP3 Expression in Colorectal Carcinoma and Adenoma

Colorectal carcinomas are the cause of high mortality and morbidity and are common i n the world and in our country. The main mechanism emphasized in colorectal carcinogenesis is the adenoma -carcinoma sequence. However, carcinoma does not develop from all adenomas. Many factors are effective in the prognosis of colorectal carcinomas. The most important prognostic parameter is TNM staging. Another is lymph node metastasis. In our study, we planned to evaluate the expression of insulin -like growth factor II m-RNA binding protein 3 (IMP3) in colorectal pathologies and its relationship with pro gnostic factors. The 30 colorectal adenocarcinomas (10 well differentiated, 10 moderately differentiated, 10 poorly differentiated), 30 colon adenomas (10 tubular, 10 villous, 10 tubulovillous) and 10 normal colonic mucosa were included in our study. The diagnostic value of the extent and intensity of staining and the relationship between stage and lymph node metastasis in patients stained with IMP3 was investigated. There was a significant correlation between IMP3 and normal mucosa-adenoma and normal mucosa-carcinoma groups (p 0.05). Significant correlations were found between IMP3 staining intensity and adenoma-carcinoma groups and between villous adenomas and other adenoma groups (p0.05). As a result, it was seen that IMP3 could be used in diagnosis, but the relationship between these markers and lymph node metastasis and stage was not significant.

PDF

___

1. Who Classification of tumors Editorial Board. Digestive system tumors Lyon (France): İnternational agency for research on cancer; 2019 (WHO classification of tumours series, 5th ed.; vol1). 157-192
2. Kumar V, Abbas AK, Aster JC. Small intestine and colon. Robbins & Cotran Pathologic Basis of Disease, 10th Edition. Philadelphia, Elsevier, 2021; 780-820.
3. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG. Epithelial Neoplasms of the Colon. Gastrointestinal Pathology, An Atlas and Text. 4’th ed, Philadelphia, Lippincott Williams&Wilkins 2017; 2071-2255.
4. Rosai J. Gastrointestinal Tract Large Bowel. Houston M. (editor) Rosai and Ackerman’s Surgical Pathology. 11’th ed, China, Mosby Company 2018; 668-720.
5. Scott, C. M., Wong, E. M., Joo, J. E., Dugue, P. A., Jung, C. H., O’Callaghan, N., et al. Genome-wide DNA methylation assessment of ’BRCA1-like’ early-onset breast cancer: data from the australian breast cancer family registry. Exp.Mol. Pathol 2018; 105: 404-410.
6. Schmiedel, D., Tai, J., Yamin, R., Berhani, O., Bauman, Y., and Mandelboim, O. The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress induced ligands ULPB2 and MICB. eLife 2016 5:e13426.doi: 10.7554/eLife.13426
7. Palanichamy J. K, Tran T. M, Howard, J. et al. RNA-binding protein IGF2BP3 targeting ofoncogenic transcripts promotes hematopoietic progenitor proliferation. J. Clin.Invest. 2016, 126, 1495–1511. doi: 10.1172/jci80046
8. Wei, Q., Zhou, H., Zhong, L., Shi, L., Liu, J., Yang, Q., et al. IMP3 expression in biopsy specimens as a diagnostic biomarker forcolorectal cancer.Hum. Pathol. 2017, 64, 137–144. doi: 10.1016/j.humpath.2017.03.013
9. Xu, W., Sheng, Y., Guo, Y., Huang, Z., Huang, Y., Wen, D., et al. IncreasedIGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo.J. Cell. Physiol 2019; 234: 18466- 18479.
10. Shaalan, Y. M., Handoussa, H., Youness, R. A., Assal, R. A., El-Khatib, A. H.,Linscheid, M. W., et al. Destabilizing the interplay between miR-1275and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Nat. Prod. Res 2018; 32: 2217- 2220.
11. Chen, H., Kong, Y., Yao, Q., Zhang, X., Fu, Y., Li, J., et al. Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients 2019; Aging11, 885- 897.
12. Bi, R., Shen, X., Zhang, W., Cheng, Y., Feng, Z., Cai, X., et al. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China withan analysis of the prognostic significance of clinicopathological parameters andIMP3 expression. Diagn. Pathol 2016; 11:17.
13. Findeis-Hosey, JJ., Xu, H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech. Histochem 2012; 87: 24-29.
14. Yuan G, Tianping L, Xiwu O, Chunfu Z, Junqiang Z, Xihu Q. IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression. Oncology Letters 2020; 20: 1423-1431.
15. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K et al. IMP3 Predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008; 14: 1701-1706
16. Zhao, W., Lu, D., Liu, L., Cai, J., Zhou, Y., Yang, Y., et al. (2017). Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability. Oncotarget 8, 93672–93687. doi: 10.18632/oncotarget.21280
17. Kulaçoğlu S, Erkılınç G. Imp3 Expression in Benign and Malignant Thyroid Tumors and Hyperplastic Nodules. Balkan Med J 2015 Jan; 32(1): 30–37. Published online 2015 Jan 1. doi: 10.5152/balkanmedj.2015.15547
18. Leslie A, Carey F.A. Partt NR, Steele. The colorectal adenoma-carcinoma sequence. R.J.C. Br J Surg 2002; 89: 845-860.
19. Jennifer J, Hosey F, Xu H. The use insulin like-growth factor 2 messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 2010; 6: 1-12.
20. Hanley KZ, Facik MZ, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 2008; 114: 49-56.
21. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, Peng Z. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009; 16: 3499- 3506.
22. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM Diffuse expression of RNA binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 2009; 16: 1711-1719.
23. Nechifor-Boila A, Nechifor-Boila A, Loghin A, Catana R, Borda A. Expression of insulin like growth factor-2 mRNA binding protein 3 (İMP3) in various normal and neoplastic human tissues. Revista Romana de Medicina de Laborator 2012; 20: 163-172.
24. Wei Q, Huang X, Fu B, Liu J, Zhong L, Yang Q, Zhao T. IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. Int J Clin Exp Pathol 2015; 8: 11024-11032.
25. Wang P.F, Wang X, Liu M et al. The Oncogenic Functions of Insulin-like Growth Factor 2 mRNA-Binding Protein 3 in Human Carcinomas. Curr Pharm Des 2020; 26: 3939- 3954.
26. Kataoka K, Kanazawa A, Nakajima A, et al. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis(CLM): a single-centered retrospective study. Surg Today 2013; 43: 1154-1161.
27. Qiu B, Ding PR, Cai L, et al. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chin J Cancer 2016; 35: 65.
28. Arredondo J, Baixauli J, Pastor C, et al. Mid term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol 2017; 19: 379-385.
29. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomized controlled trial. Lancet Oncol 2012; 13: 1152-1160.
30. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Color Dis 2014; 29: 1031-1042.
31. Cerar A, Zidar N, Vodopivec B. Colorectal carcinoma in endoscopic biopsies; additional histologic criteria for the diagnosis. Pathol Res Pract 2004; 200: 657-662.
32. Hirose M, Fukui H, Igarashi Y, et al. Detection of desmoplastic reaction in biopsy specimens is useful for predicting the depth of invasion of early colorectal cancer: a Japanese collaborative study. J Gastroenterol 2010; 45: 1212-1218.